Clinical Trials
364 trialsClinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
CESM
European Institute of Oncology
Digital Health Intervention to Improve Health Care and Outcomes for Breast Cancer Patients
Coordinación de Investigación en Salud, Mexico
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
NeoPACT
University of Kansas Medical Center
PROTECT
Fondazione IRCCS Policlinico San Matteo di Pavia
First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients
Fudan University
VUBAR
Universitair Ziekenhuis Brussel
BreastImmune03
Centre Leon Berard
Study of Dotatate Imaging in Breast Cancer
Hoag Memorial Hospital Presbyterian
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
Consorzio Oncotech
Olaparib Maintenance Therapy in Metastatic Breast Cancer
National Taiwan University Hospital
FACT-2
West Cancer Center
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Academic and Community Cancer Research United
Pyrotinib Combined With Capecitabine and Bevacizumab for Patients With HER2 Positive Breast Cancer and Brain Metastases
Tongji Hospital
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy
Chung Shan Medical University
WinPro
St Vincent's Hospital
SPARK
Fudan University
Trigger Point Injections for Post-Mastectomy Pain Syndrome
Instituto do Cancer do Estado de São Paulo
ROME
Fondazione per la Medicina Personalizzata
18F-fluoroestradiol (FES) PET/CT for Breast Cancer
Hoag Memorial Hospital Presbyterian
MorphineGEL
Instituto Nacional de Cancer, Brazil
Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer
Henan Cancer Hospital
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
Henan Cancer Hospital
CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER
European Institute of Oncology
Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer
Qilu Hospital of Shandong University
MARIO-3
Infinity Pharmaceuticals, Inc.
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
Ottawa Hospital Research Institute
Role of Curcumin in Paclitaxel Induced PN
Ain Shams University
HIST-RIC
Institut Paoli-Calmettes
Pilot Trial to Assess 68Ga Bombesin PET/CT (NeoB) Imaging for Staging of Breast Cancer
St Vincent's Hospital, Sydney
PYTHON
Tianjin Medical University Cancer Institute and Hospital
Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer
Taizhou Hospital
Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position
Shanghai Proton and Heavy Ion Center
BREAKFAST-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
DAP-Her-01
Henan Cancer Hospital
Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients
Consorzio Oncotech
A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.
Tianjin Medical University Cancer Institute and Hospital
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy
Tianjin Medical University Cancer Institute and Hospital
Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Yantai Yuhuangding Hospital
VinCaT
National Cancer Institute, Naples
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
FB-12
NSABP Foundation Inc
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
Assiut University
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Sun Yat-sen University